A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release, as well as producing antidepressant and anxiolytic effects in animal studies, and it was also being researched for treatment of cognitive dysfunction. All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.
Clinical studies have revealed that camptocormia may be hereditary; however, the inheritance mechanism remains unclear. Current areas of research include molecular and genetic studies aimed at elucidating a possible inheritance model along with molecular pathological mechanisms and proteins responsible for BSS. This research will help will facilitate improvement in the classification, diagnosis, and treatment of the condition. In addition, new technologies and animal models of postural abnormalities are being developed to understand camptocormia and design more effective treatment methods.
1993/2533) Medicines (Applications for Grant of Product Licences—Products for Human Use) Regulations 1993 (S.I. 1993/2538) Medicines (Standard Provisions for Licences and Certificates) Amendment (No. 2) Regulations 1993 (S.I. 1993/2539) Birmingham Women's Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2541) Northern Birmingham Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2542) South Birmingham Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2543) Churchill John Radcliffe National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2544) City Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2545) Derbyshire Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2546) Derbyshire Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2547) Dewsbury Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2548) East Wiltshire Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2549) East Yorkshire Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2550) George Eliot Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2551) Hereford Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2552) Hereford and Worcester Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I.
Vitamin K: CID 5280483 from PubChem Vitamin K1 (phylloquinone, phytomenadione): CID 5284607 from PubChem Vitamin K2 (menaquinone 6): CID 5283547 from PubChem Vitamin K3 (menadione): CID 4055 from PubChem
Sources: en.wikipedia.org
Portugal has a predominantly universal tax-funded health care system, called Serviço Nacional de Saúde (SNS), that operates alongside public-sector health insurance schemes called health subsystems funded mainly through employee and employer contributions, as well as private voluntary health insurance. Primary and hospital care are provided by both public and private entities, with the private sector and complementing services offered by the SNS. In 2023, Portugal had the 3rd lowest public share on health spending in the European Union and over half of public hospitals in technical insolvency in 2020. Portugal has a high level of health inequity in the OECD, driven by limited public spending, uneven distribution of services, low household income, long waiting times, and policy shortcomings. Portugal ranked 23rd in the world in 2024 in life expectancy with 85.4 years for women and 79.8 years for men, and it had an infant mortality rate of 2.7 deaths per 1,000 live births. In 2022, the leading cause of death were cardiovascular diseases, at 25.4%. Portugal presents several adverse public-health indicators, including the 3rd lowest share of people reporting good health in the European Union, in 2024, at 54%, the highest alcohol consumption with 11.9 litres (2.6 imp gal; 3.1 US gal) consumed per person, in 2020, and the highest share of adult population living a sedentary lifestyle, in 2022, at 73%, a pattern reinforced by limited active-transport infrastructure and unsafe conditions for pedestrians and cyclists.
=== Solvent/detergent (S/D) inactivation === This process, developed by the New York Blood Center, is the most widely used viral inactivation method to date. It is predominantly used in the blood plasma industry, by over 50 organizations worldwide and by the American Red Cross. This process is only effective for viruses enveloped in a lipid coat, however. The detergents used in this method interrupt the interactions between the molecules in the virus's lipid coating. Most enveloped viruses cannot exist without their lipid coating so are destroyed when exposed to these detergents. Other viruses may not be destroyed but they are unable to reproduce rendering them non-infective. The solvent creates an environment in which the aggregation reaction between the lipid coat and the detergent happen more rapidly. The detergent typically used is Triton X-100. This process has many of the advantages of the "traditional" removal techniques. This process does not denature proteins, because the detergents only affect lipids and lipid derivatives. There is a 100% viral death achieved by this process and the equipment is relatively simple and easy to use. Equipment designed to purify post-virus inactivated material would be necessary to guard against contamination of subsequent process streams. S/D treatment utilizes readily available and relatively inexpensive reagents, but these reagents must be removed from the product prior to distribution which would require extra process steps.
Newell has been critical of the direction that Microsoft has taken with making Windows a closed architecture similar to Apple's products, and has stated that he believes that the changes made in Windows 8 are "a catastrophe for everyone in the [personal computer] space". Newell identified the open-source Linux platform as an ideal platform for Steam and said the only thing holding back its adoption is the lack of games. In 2012, Valve announced that they were working on a console-PC hybrid for the living room, dubbed by media as the "Steam Box". A precursor to such a unit is SteamOS, a freely available Linux-based operating system that builds upon the Steam client functionality that includes media services, live streaming across home networks, game sharing within families, and parental controls. SteamOS was officially announced in September 2013 as the first of several announcements related to the Steam Machine platform as well as its unique game controller. In May 2014, Valve announced that the company's own SteamOS-powered Steam Machine would be delayed until 2015 due to problems with the game controller. In 2015, Alienware, ZOTAC, and CyberPowerPC launched its versions of the Steam Machine. By June 2016, fewer than half a million had been sold. While the Steam Machine line has been effectively canceled, Valve continued to manufacture and sell Steam Controllers until late November 2019, and publishes both mobile apps and software for the Steam Link, allowing in-home streaming.
The small intestine starts at the pyloric sphincter, and finishes at the ileocecal valve. Partially digested food starts to arrive in the small intestine as semi-liquid chyme, one hour after it is eaten. The stomach is half empty after an average of 1.2 hours. After four or five hours the stomach has emptied. In the small intestine, the pH becomes crucial; it needs to be finely balanced in order to activate digestive enzymes. The chyme is very acidic, with a low pH, having been released from the stomach and needs to be made much more alkaline. This is achieved in the duodenum by the addition of bile from the gall bladder combined with the bicarbonate secretions from the pancreatic duct and also from secretions of bicarbonate-rich mucus from duodenal glands known as Brunner's glands. The chyme arrives in the intestines having been released from the stomach through the opening of the pyloric sphincter. The resulting alkaline fluid mix neutralises the gastric acid which would damage the lining of the intestine. The mucus component lubricates the walls of the intestine.
== See also == 3,4-Dihydroxyamphetamine (HHA; α-methyldopamine) 4-Hydroxy-3-methoxyamphetamine (HMA) 4-Hydroxy-3-methoxymethamphetamine (HMMA) 2,4,5-Trihydroxyamphetamine (THA) 2,4,5-Trihydroxymethamphetamine (THMA) 3,4-Dihydroxymethcathinone (HHMC) 4-Hydroxy-3-methoxymethcathinone (HMMC)
Sources: en.wikipedia.org
== Biosynthetic mechanism == Hyaluronic acid (HA) is a linear glycosaminoglycan (GAG), an anionic, gel-like, polymer, found in the extracellular matrix of epithelial and connective tissues of vertebrates. It is part of a family of structurally complex, linear, anionic polysaccharides. The carboxylate groups present in the molecule make it negatively charged, therefore allowing for successful binding to water, and making it valuable to cosmetic and pharmaceutical products. HA consists of repeating β4-glucuronic acid (GlcUA)-β3-N-acetylglucosamine (GlcNAc) disaccharides, and is synthesized by hyaluronan synthases (HAS), a class of integral membrane proteins that produce the well-defined, uniform chain lengths characteristic to HA. There are three existing types of HASs in vertebrates: HAS1, HAS2, HAS3; each of these contribute to elongation of the HA polymer. For an HA capsule to be created, this enzyme must be present because it polymerizes UDP-sugar precursors into HA. HA precursors are synthesized by first phosphorylating glucose by hexokinase, yielding glucose-6-phosphate, which is the main HA precursor. Then, two routes are taken to synthesize UDP-n-acetylglucosamine and UDP-glucuronic acid which both react to form HA. Glucose-6-phosphate gets converted to either fructose-6-phosphate with hasE (phosphoglucoisomerase), or glucose-1-phosphate using pgm (α-phosphoglucomutase), where those both undergo different sets of reactions. UDP-glucuronic acid and UDP-n-acetylglucosamine get bound together to form HA via hasA (HA synthase).
Increased heart rate Vasodilation leading to decreased systemic vascular resistance, and high-output heart failure Elevated jugular venous pressure Dyspnea (shortness of breath) on exertion Paroxysmal nocturnal dyspnea Peripheral edema (swelling of lower legs) or generalized edema (swelling throughout the body) Dilated cardiomyopathy
Mukasey (1963), attorney general of the United States; former chief judge of the United States District Court for the Southern District of New York David Saxe (1963), associate justice of the Appellate Division of the New York Supreme Court, First Judicial Department and former judge on the New York Supreme Court Peter Zimroth (1963), assistant U.S. attorney for the Southern District of New York and assistant New York County district attorney, professor at the New York University School of Law Barry Kamins (1965), New York City Criminal Court judge and professor at the Fordham University School of Law and Brooklyn Law School Howard Matz (1965), senior judge of the United States District Court for the Central District of California Flemming L. Norcott Jr. (1965), former associate justice of the Connecticut Supreme Court Joel Klein (1967), assistant attorney general of the United States; chancellor of the New York City Department of Education Anthony C. Moscato (1967), acting inspector general of the Department of Justice and director of the Executive Office for United States Attorneys David M. Becker (1968), two-time general counsel of the U.S. Securities and Exchange Commission Nicholas G. Garaufis (1969), judge of the United States District Court for the Eastern District of New York and former chief counsel of the Federal Aviation Administration Jonathan D.
== Mechanism of action == The primary mechanism of action by PDRN is the adenosine A2A receptor pathway, which is activated following enzymatic degradation of the deoxyribonucleotide polymers. Adenosine acts the primary ligand which binds to the G protein-coupled receptor A2A leading to an increase in intracellular cyclic AMP (cAMP) levels. This secondary messenger activates protein kinase A (PKA) acting as a signaling cascade of several pathways downstream.Thus, enhacing tissue repair through upregulation of PI3K/Akt and vascular endothelial growth factor (VEGF). The activation of the A2A pathway is observed to be conserved across various PDRN sources, yet it activates different downstream pathways depending on the type of tissue and injury. Additionally, PDRN contributes to the salvage pathway, which is a metabolic mechanism that supports nucleotide synthesis for processes like DNA replication and celullar proliferation. For injuries needing faster regeneration, this nucleoside input is essential, highlighling the importance of both signaling and metabolic pathways for optimal tissue repair.
Sinsemilla (Spanish for "without seed") is the dried, seedless (i.e. parthenocarpic) infructescences of female cannabis plants. Because THC production drops off once pollination occurs, the male plants (which produce little THC themselves) are eliminated before they shed pollen to prevent pollination, thus inducing the development of parthenocarpic fruits gathered in dense infructescences. Advanced cultivation techniques such as hydroponics, cloning, high-intensity artificial lighting, and the sea of green method are frequently employed as a response (in part) to prohibition enforcement efforts that make outdoor cultivation more risky. "Skunk" refers to several named strains of potent cannabis, grown through selective breeding and sometimes hydroponics. It is a cross-breed of Cannabis sativa and C. indica (although other strains of this mix exist in abundance). Skunk cannabis potency ranges usually from 6% to 15% and rarely as high as 20%. The average THC level in coffee shops in the Netherlands is about 18–19%. The average levels of THC in cannabis sold in the United States rose dramatically between the 1970s and 2000. This is disputed for various reasons, and there is little consensus as to whether this is a fact or an artifact of poor testing methodologies. According to Daniel Forbes writing for slate.com, the relative strength of modern strains are likely skewed because undue weight is given to much more expensive and potent, but less prevalent, samples.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.